Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents ...

Image credit Weight loss is an incredible journey; if you’ve been through it, you know how frustrating and overwhelmin ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

GLP-1R agonist use is associated with a decrease in IOP, although this correlation is not statistically significant.

Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

GLP-1 receptor agonists are being recommended on social media, raising questions about who can see the content and what the ...

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in one year.

Improvements in the Dermatology Life Quality Index score and hidradenitis suppurativa flares were seen in people who achieved ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...